These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 2039994)

  • 21. Induction by interferon-alpha of tumoricidal activity of adherent mononuclear cells from human blood: monocytes as responder and effector cells.
    Sone S; Utsugi T; Shirahama T; Ishii K; Mutsuura S; Ogawara M
    J Biol Response Mod; 1985 Apr; 4(2):134-40. PubMed ID: 3998764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The low affinity 40,000 Fc gamma receptor and the transferrin receptor can be alternative or simultaneous target structures on cells sensitive for natural killing.
    Perl A; Looney RJ; Ryan DH; Abraham GN
    J Immunol; 1986 Jun; 136(12):4714-20. PubMed ID: 3011902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lysis of human solid tumor cells by lymphokine-activated natural killer cells.
    Itoh K; Tilden AB; Balch CM
    J Immunol; 1986 May; 136(10):3910-5. PubMed ID: 3084648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heterogeneous response of human colon cancer cells to the cytostatic and cytotoxic effects of recombinant human cytokines: interferon-alpha, interferon-gamma, tumor necrosis factor, and interleukin-1.
    Morikawa K; Fidler IJ
    J Biol Response Mod; 1989 Apr; 8(2):206-18. PubMed ID: 2499665
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor necrosis factor-alpha enhances cytolytic activity of human natural killer cells.
    Ostensen ME; Thiele DL; Lipsky PE
    J Immunol; 1987 Jun; 138(12):4185-91. PubMed ID: 3108384
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resistance to natural killer cell-mediated cytolysis by a pleiotropic drug-resistant human erythroleukemia (K562-R) cell line.
    Yanovich S; Hall RE; Weinert C
    Cancer Res; 1986 Sep; 46(9):4511-5. PubMed ID: 2425955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro.
    Nakamura M; Nagano H; Sakon M; Yamamoto T; Ota H; Wada H; Damdinsuren B; Noda T; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Nakamori S; Dono K; Monden M
    J Hepatol; 2007 Jan; 46(1):77-88. PubMed ID: 17045692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interactive effects of alpha-interferon A/D and interleukin 2 on murine lymphokine-activated killer activity: analysis at the effector and precursor level.
    Chikkala NF; Lewis I; Ulchaker J; Stanley J; Tubbs R; Finke JH
    Cancer Res; 1990 Feb; 50(4):1176-82. PubMed ID: 2297766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Studies on the mechanism of natural killer cytotoxicity. III. Activation of NK cells by interferon augments the lytic activity of released natural killer cytotoxic factors (NKCF).
    Wright SC; Bonavida B
    J Immunol; 1983 Jun; 130(6):2960-4. PubMed ID: 6189908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Augmentation of natural immunity and correlation with tumor response in melanoma patients treated with human lymphoblastoid interferon.
    Neefe JR; Phillips EA; Treat J
    Diagn Immunol; 1986; 4(6):299-305. PubMed ID: 3102149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term killing of natural killer-resistant target cells by interferon-alpha-, interferon-gamma-, and interleukin-2-activated natural killer cells.
    Sarzotti M; Klimpel GR; Baron S
    Nat Immun Cell Growth Regul; 1989; 8(2):66-75. PubMed ID: 2503715
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation of the antigenic phenotype of human melanoma cells by recombinant interferons.
    Giacomini P; Gambari R; Barbieri R; Nisticò P; Tecce R; Pestka S; Gustafsson K; Natali PG; Fisher PB
    Anticancer Res; 1986; 6(5):877-84. PubMed ID: 2432832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low doses of anticancer drugs increase susceptibility of tumor cells to lysis by autologous killer cells.
    Matsuoka H; Eura M; Chikamatsu K; Nakano K; Kanzaki Y; Masuyama K; Ishikawa T
    Anticancer Res; 1995; 15(1):87-92. PubMed ID: 7733647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alpha-interferon structure and natural killer cell stimulatory activity.
    Li BL; Zhao XX; Liu XY; Kim HS; Raska K; Ortaldo JR; Schwartz B; Pestka S
    Cancer Res; 1990 Sep; 50(17):5328-32. PubMed ID: 2201435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Augmentation by anti-T3 antibody of the lymphokine-activated killer cell-mediated cytotoxicity.
    Ting CC; Hargrove ME; Yun YS
    J Immunol; 1988 Aug; 141(3):741-8. PubMed ID: 3260909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natural killer-sensitive targets stimulate production of TNF-alpha but not TNF-beta (lymphotoxin) by highly purified human peripheral blood large granular lymphocytes.
    Peters PM; Ortaldo JR; Shalaby MR; Svedersky LP; Nedwin GE; Bringman TS; Hass PE; Aggarwal BB; Herberman RB; Goeddel DV
    J Immunol; 1986 Oct; 137(8):2592-8. PubMed ID: 3760569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interferon-induced changes in the susceptibility of murine and human lymphoma cells to natural cytotoxic lymphocytes.
    Giuliani-Bonmassar A; Graziani G; Frati L; Bonmassar E
    Int J Tissue React; 1984; 6(1):35-41. PubMed ID: 6585352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased sensitivity to MHC-nonrestricted lysis of BL6 melanoma cells by transfection with class I H-2Kb gene.
    Gorelik E; Jay G; Kwiatkowski B; Herberman RB
    J Immunol; 1990 Sep; 145(5):1621-32. PubMed ID: 2384672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
    Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A
    Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms of interaction of interferon and 5-fluorouracil in solid tumors.
    Neefe JR; John W
    Semin Oncol; 1991 Oct; 18(5 Suppl 7):77-82. PubMed ID: 1719644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.